Burgdorf – Ypsomed is adding to existing infrastructure at the Solothurn facility and creating around 100 new jobs over the coming years.
The total investment in manufacturing equipment and infrastructure is CHF 50 million. A significant part of this extension is yet another major project for our long-standing partner, Sanofi: injection system components will be manufactured on an additional production line starting in the second half of 2016. The annual capacity will be in the double-digit millions. Ypsomed will also be expanding capacity for its own products, including the UnoPenTM, with additional smart manufacturing infrastructure.